Completed PHASE2 INTERVENTIONAL 1-arm NCT00059813

Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer

A Phase II Trial of G3139 (Genasense) Anti-Bcl-2 Antisense Oligonucleotide Plus Alpha-Interferon in Metastatic Renal Cancer

Sponsor: National Cancer Institute (NCI)

Conditions Recurrent Renal Cell Cancer Stage IV Renal Cell Cancer

Interventions oblimersen sodium pharmacological study recombinant interferon alfa

Updated 6 times since 2017 Last updated: Aug 23, 2013 Started: Aug 31, 2003 Primary completion: Jun 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00059813, this PHASE2 trial focuses on Recurrent Renal Cell Cancer and Stage IV Renal Cell Cancer and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 6 times since 2003, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Aug 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Duarte, United States